The global Duchenne Muscular Dystrophy Treatment Market size was estimated at USD 3.8 Bn in 2021, growing at a CAGR of 38.2% during the forecast period 2022-2028. Duchenne muscular dystrophy (DMD) is a genetic disorder and it is one of the 9 types of muscular dystrophy, which is characterized by progressive degeneration and weakness of muscle. It is caused due to the absence of dystrophin protein which helps to keep muscle cells intact. The onset of symptoms will be from early childhood in the age of 3-5. Guillaume Benjamin Amand Duchenne was the first French neurologist to describe Duchenne muscular dystrophy in the 1860s. There is no known cure for Duchenne muscular dystrophy but the treatment is given to control the symptoms to maximize the quality of life of the patient. There are very few products are marketed for the treatment of Duchenne muscular dystrophy-like Translama, Exodus 51, and Emflaza. Presently this market is in the research phase majorly and focuses on the ongoing clinical trials for the development of innovative products. Government organizations are focussing on the prevention of Duchenne muscular dystrophy. For instance, world Duchenne awareness day was initiated by The United Parent Projects Muscular Dystrophy (UPPMD) with the motto of rising awareness regarding Duchenne muscular dystrophy globally and they have declared 07 th September as the world’s Duchenne awareness day. In 2015, U.S. FDA has published specific guidance for the development of drugs to treat Duchenne muscular dystrophy. Innovative approaches like utrophin modulation which is going to launch during the forecast period to treat DMD and approvals for the drugs such as ezutromid of summit therapeutics a phase II clinical trial drug which received orphan drug designation fast approval from U.S.FDA and BioMarin Pharmaceuticals is developing an exon-skipping drisapersen which is phase III clinical trial evaluation all these developments are expected to offer lucrative opportunities for Duchenne Muscular Dystrophy Treatment Market.